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Personalized cancer vaccine strategy elicits polyfunctional
T cells and demonstrates clinical benefits in ovarian cancer
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Christine Goepfert4,5, David Tarussio3, Stephanie Tissot3, Drew A. Torigian6, Harvey L. Nisenbaum6, Brian J. Stevenson2,
Hajer Fritah Guiren2, Ritaparna Ahmed2, Anne-Laure Huguenin-Bergenat2, Emese Zsiros1, Michal Bassani-Sternberg2, Rosemarie Mick7,
Daniel J. Powell Jr. 1, George Coukos2, Alexandre Harari 2,3,9 and Lana E. Kandalaft 2,3,9✉
T cells are important for controlling ovarian cancer (OC). We previously demonstrated that combinatorial use of a personalized
whole-tumor lysate-pulsed dendritic cell vaccine (OCDC), bevacizumab (Bev), and cyclophosphamide (Cy) elicited neoantigen-
specific T cells and prolonged OC survival. Here, we hypothesize that adding acetylsalicylic acid (ASA) and low-dose interleukin (IL)-
2 would increase the vaccine efficacy in a recurrent advanced OC phase I trial (NCT01132014). By adding ASA and low-dose IL-2 to
the OCDC-Bev-Cy combinatorial regimen, we elicited vaccine-specific T-cell responses that positively correlated with patients’
prolonged time-to-progression and overall survival. In the ID8 ovarian model, animals receiving the same regimen showed
prolonged survival, increased tumor-infiltrating perforin-producing T cells, increased neoantigen-specific CD8+ T cells, and reduced
endothelial Fas ligand expression and tumor-infiltrating T-regulatory cells. This combinatorial strategy was efficacious and also
highlighted the predictive value of the ID8 model for future ovarian trial development.
npj Vaccines            (2021) 6:36 ; https://doi.org/10.1038/s41541-021-00297-5
INTRODUCTION
T cells are essential for controlling cancer progression. Prior
studies in ovarian cancer (OC) patients consistently reported a
correlation between CD3+ tumor-infiltrating lymphocytes (TILs)
and overall survival (OS)1–4. This observation provides a rationale
for using immunotherapies to mobilize endogenous antitumor
T cells. We previously demonstrated that vaccinating OC patients
with autologous dendritic cells (DCs) pulsed with oxidized
autologous whole-tumor lysate (termed OCDC) elicited T cells
against shared tumor-associated antigens, including HER-2/neu,
MUC1, and WT1 and private neoantigens5,6.
OC harbors immunosuppressive mechanisms that hinder
antitumor immunity and combinatorial therapeutic strategies are
needed to overcome them. In the OC tumor microenvironment
(TME), vascular endothelial growth factor (VEGF) and T-regulatory
(Treg) cells are important immunosuppressive barriers that could
drive tumor angiogenesis, as well as prevent effective homing,
expansion, and function of tumor-specific T cells7. Most OCs
express VEGF and increased sera VEFG levels have been correlated
with poor survivals8–10. Treg cells suppress tumor-specific T cells
and contribute to tumor progression11,12. They also accumulated
in advanced OCs12. By targeting VEGF and Treg cells with
bevacizumab (Bev) and cyclophosphamide (Cy), respectively, we
previously demonstrated that OCDC used in combination with
these agents led to enhanced OC survivals (NCT01132014; www.
clinicaltrials.gov)6. Inhibiting VEGF could also lead to “normal-
ization” of tumor vasculature, improving oxygen, nutrient, and
chemotherapy delivery to increase tumor toxicity and reduce
ascites fluid formation13,14.
Here, we sought to enhance the antitumor T-cell responses of
OCDC by incorporating acetylsalicylic acid (ASA) and low-dose
interleukin (IL)-2 in the combinatorial strategy. ASA, a classical
nonsteroidal anti-inflammatory drug (NSAID), is widely used for
treating fever, pain, and inflammatory diseases15. It irreversibly
inhibits cyclooxygenase (COX)1 and COX2 enzymes and thereby
inhibits prostaglandin E2 (PGE2) synthesis. Long-term ASA use has
been associated with reduced cancer incidences and mortalities,
including in ovarian, colorectal, breast, and esophageal cancers16–18.
We previously demonstrated that the OC tumor endothelium acted
as a potent immune barrier by expressing the death mediator Fas
ligand (FasL/CD95L) that preferentially killed CD8+ T cells, and such
FasL expression was cooperatively induced by tumor-derived VEGF,
IL-10, and PGE219. By inhibiting VEGF and PGE2 with ASA and an anti-
VEGF blocking antibody, respectively, the tumor endothelial FasL
expression was attenuated and that facilitated a substantial
infiltration of tumor-suppressing CD8+ TILs in the ID8 OC tumor
model19. In human OC, COX1 and COX2 overexpression was
significantly associated with lower numbers of CD8+ TILs and worse
prognosis20,21. Hence, ASA and anti-VEGF-blocking antibodies are
useful in modulating OC tumor endothelial FasL expression. IL-2 is a
major T-cell growth factor that can assist in the in vivo expansion of
antigen-specific T cells and lymphokine-activated killer (LAK)
cells22–24. As OC patients exhibit spontaneous antitumor immune
responses, IL-2 therapy could help to activate preexisting
immunity or enhance immunomodulatory therapy. In OC, low-
dose subcutaneous IL-2 in combination with 13-cis-retinoic acid
could improve progression-free survival (PFS) and OS25. VEGF was
also decreased, and the CD4+/CD8+ ratio improved in patients25.
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IL-2 could also increase adoptive T-cell therapies and DC vaccine
effectiveness26–29. In phase II metastatic melanoma study,
combinatorial treatment with DC vaccine (peptide-pulsed or
whole-tumor lysate), IL-2 and metronomic Cy and Celecoxib
(a COX2 inhibitor) was safe, and 16 out of 28 (57%) patients
experienced stable diseases (NCT00197912; www.clinicaltrials.
gov)30. Thus, IL-2 could potentially benefit the proliferation and
function of effector T cells elicited by OCDC in this study.
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We report here the promising results of a combinatorial strategy
that comprised OCDC, Bev, ASA, Cy, and low-dose IL-2 in a phase I
trial with recurrent advanced OC patients (NCT01132014; www.
clinicaltrials.gov), and in the syngeneic mouse ID8 OC model. We
demonstrated that this combinatorial strategy was effective and
elicited polyfunctional (IFN-γ, TNF-α, granzyme, and perforin) vaccine-
specific T-cell responses in OC patients that correlated with
prolonged time-to-progression and OS. In the ID8 model, animals
receiving the same regimen showed prolonged survival, increased
CD3+ and CD8+ TILs, increased neoantigen-specific CD8+ T-cell
responses that were correlated with reduced tumor burden, and a
systemic effect with elevated T helper (Th)1-polarizing plasma
chemokines. Particularly, elevated sera CXCL9 was positively
correlated with increased CD3+ and CD8+ TILs. The similar trend
observed in the phase I OC trial and in the ID8 model highlighted the
relevance of using the ID8 model for OC clinical translation.
RESULTS
The addition of ASA and low-dose IL-2 to an OCDC-Bev-Cy
combinatorial regimen induced an immune response and
prolonged time-to-progression and OS in recurrent OC
patients
We previously demonstrated that the addition of Cy to OCDC+
Bev significantly increased antigen-specific T-cell responses and OS
rate at 2 years6. In this study, we investigated if adding ASA and
low-dose IL-2 could further enhance antitumor T-cell responses in a
phase I trial of 30 platinum-pretreated, immunotherapy-naive
recurrent advanced OC patients (NCT01132014) (ten patients per
cohort). Treatment combinations and schedules are shown in
Fig. 1A. Patients were followed up to 3 years and evaluated for
time-to-progression and 3-years OS from the initiation of OCDC-
Bev-Cy combinatorial regimens (i.e., day 0; Fig. 1A). Most patients
had received several prior lines of chemotherapy, and their
clinicopathologic characteristics, treatment details, and 3-year OS
outcome were described in Table 1. All patients received
intravenous Cy (200mg/m2) followed by OCDC (5–10 × 106 DCs/
dose given intranodally every 3 weeks, five doses in total) plus
intravenous Bev (anti-VEGF blocking antibody, 15mg/kg, given on
the same day as OCDC) on the next day every 3 weeks. Cohort B
and C received additional oral ASA (325mg of enteric-coated
aspirin from the day of first OCDC to day 84 or as tolerated). Cohort
C also received subcutaneous low-dose IL-2 (2MIU/dose given for 5
consecutive days following each OCDC). As Cohort A was
previously described6, this study reported findings in Cohorts B
and C patients.
Cohort B and C treatment regimens were safe and well-
tolerated. Few grade 3 adverse events (AEs) such as hypotension,
proteinuria, vomiting, decreased absolute neutrophil count,
thrombocytosis, and skin infection were observed and were
effectively managed. We did not observe any grade 4 AEs (Fig. 1B).
The commonest grade 3 AE in both cohorts was hypotension
(5 occurrences). First, we investigated the kinetics of OCDC
vaccine-elicited T cells at day 20-, day 62-, and end-of-study (EOS).
We observed that Cohort C patients C-01 and C-09, who showed
prolonged time-to-progression and/or 3-years OS, demonstrated a
persistent increase in the number of IFN-γ-secreting vaccine-
specific T cells at EOS that was significantly higher than at pre-
vaccine (day −1) (Fig. 1C; ** indicated that P < 0.0005 comparing
pre-vaccine and EOS T cells in the same patient). Less potent
vaccine immunogenicity was observed in Cohort B patients B-02
and B-06 who showed shorter time-to-progression and 3-years OS
(Fig. 1C). Next, we sought to determine if there was a positive
correlation between the increasing number of IFN-γ-secreting
vaccine-specific T cells elicited during treatment and a prolonged
time-to-progression in Cohorts B and C patients. Of the 12 patients
(6 from each cohort) whom we had available PBMCs for
evaluation, we compared the highest number of vaccine-specific
T cells elicited (i.e., immunogenicity) during treatment in each
patient and the patient’s corresponding time-to-progression. We
demonstrated that patients who displayed a higher number of
IFN-γ-secreting vaccine-specific T cells also experienced a longer
time-to-progression (r2= 0.775; P= 0.0002) (Fig. 1D, right panel).
Three out of six Cohort C patients (Fig. 1D, left panel, blue bars) as
compared to one out of six Cohort B patients (Fig. 1D, left panel,
red bars) experienced a prolonged time-to-progression of
≥1000 days (indicated with black arrows). We also demonstrated
a significant positive correlation between OCDC immunogenicity
and a prolonged 3-years OS in these patients (r2= 0.404; P=
0.0264) (Fig. 1E, right panel). Of the 12 patients analyzed, all 6
Cohort C patients remained alive at 3-years OS when compared to
2 (Patients B-01 and B-06) out of the 6 Cohort B patients (Fig. 1E
right panel; black arrows indicated that patients were alive at
3-years, and Fig. 1G (P= 0.014)). Overall, these Cohort C patients
showed a significantly higher number of vaccine-specific
T cells at EOS than Cohort B patients (P= 0.037) (Fig. 1F). In
summary, 80% (eight of ten) of Cohort C patients remained alive
at 3-years OS when compared to Cohort A (40%; four of ten)
and B (40%; four of ten) patients (Table 1; Cohort A data not
shown). Hence, the results demonstrated that the addition
of both ASA and low-dose IL-2 to an OCDC-Bev-Cy combinatorial
regimen increased vaccine immunogenicity and clinical benefit in
OC patients.
The addition of ASA and low-dose IL-2 to an OCDC-Bev-Cy
combinatorial regimen elicits polyfunctional T-cell responses
in OC patients
Having observed that Cohort C regimen induced a stronger OCDC
vaccine-specific T-cell response than Cohort B regimen, we sought
to determine if the responding CD4+ and CD8+ T cells were
qualitatively different between these two cohorts at EOS. Showing
Cohort C-07 patient as an example response (Fig. 2A), we
Fig. 1 Adding ASA and low-dose IL-2 to OCDC-Bev-Cy combinatorial regimen prolonged OC survival. A OC patients were enrolled in phase
I, a single-center study (ten patients/cohort). Cohort A received OCDC, Bev, and Cy. Cohort B received additional daily oral ASA (325mg of
enteric-coated aspirin) from day 0 to 84, while Cohort C received oral ASA and subcutaneous low-dose IL-2 (2MIU/dose given for 5
consecutive days following each OCDC). Patients were followed up for 3 years. Asterisks indicated time points that the patient’s PBMCs were
obtained (day −1 (pre-vaccine), 20, 62, and 114) for immune analysis. B Number of adverse events (AEs) in patients during treatment. C OCDC
vaccine-specific responses in Cohort B and C patients. PBMCs were stimulated ex vivo with OCDC or media as background control. The results
were subtracted from pre-vaccine readout and reported as a spot-forming unit (SFU)/1 × 106 cells±standard error of the mean (SEM).
D Number of OCDC vaccine-specific T cells detected by IFN-γ ELISpot and time-to-progression in Cohort B and C patients. Left panel, patients
were ranked based on the magnitude of OCDC vaccine-specific T-cell responses detected during treatment (background subtracted) (n= 6
patients per cohort]. Right panel, linear regression analysis indicated a positive correlation between increasing vaccine immunogenicity and
increasing time-to-progression (r2= 0.775; P= 0.0002). E Number of OCDC vaccine-specific T cells detected by IFN-γ ELISpot and 3-years
overall survival (OS) in Cohort B and C patients. Left panel, patients were ranked as in (D). Right panel, linear regression analysis indicated a
positive correlation between increasing vaccine immunogenicity and increasing 3-years OS (r2= 0.404; P= 0.0264). F Number of OCDC
vaccine-specific T cells detected in Cohort B and C patients at EOS (Student’s t test; P= 0.0264). G Stacked bars showing % of Cohort B and C
patients alive (solid red and blue, respectively) or deceased (white) at 3-years OS. P value determined with Fisher’s exact test.
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demonstrated that CD4+ and CD8+ T cells elicited in both cohorts
were polyfunctional, i.e., simultaneously displayed a high number
of functions including expression of IFN-γ, IL-2, TNF-α, CD137, and
cytolytic molecules perforin and granzyme B (Fig. 2B). Particularly,
vaccine-specific CD8+ T cells elicited by Cohort C regimen were
significantly more polyfunctional than those elicited by Cohort B
regimen (P= 0.016) (Fig. 2B, right panel and Supplementary Fig.
1A showing gating strategy). We further demonstrated that
significant polyfunctional vaccine-specific CD4+ and CD8+ T-cell
populations were elicited in Cohort C patients and not in Cohort B
patients; these T cells predominantly expressed a combination of
perforin and granzyme B, IFN-γ, and TNF-α (Supplementary
Fig. 1B, C).
Next, we evaluated the expression of activation/exhaustion
markers including 2B4 (CD244), CTLA4, LAG3, PD1, TIGIT, and TIM3
on vaccine-specific CD4+ and CD8+ T cells between Cohorts B and
C, and did not observe any significant differences (Fig. 2C and
Supplementary Fig. 2A showing gating strategy). We also found
no significant differences in the CD4+CD25+FOXP3+ Treg cell
populations and their expression markers in the two cohorts
(Supplementary Fig. 2B showing gating strategy and Supplemen-
tary Fig. S2C, D). We did observe trends toward a higher
proportion of IL-17+CD4+ T cells, as well as a higher frequency
of Ki67-expressing CD8+ T cells elicited by OCDC vaccine in Cohort
C (Supplementary Fig. 2E, F). Finally, we sought to identify
immune responses against tumor neoepitopes in an OC patient
(B-08) whom we had available tumor and PBMC materials. To this
end, HLA-restricted neoepitopes were predicted as previously
described6,31 (Supplementary Table 1). We detected both CD4+
and CD8+ T-cell responses against pools of private neoepitopes
(Fig. 2D). We further validated a positive CD4+ T-cell response to a
putative predicted HLA Class II-restricted neoepitope combined
with the lack of reactivity against the wild-type peptide sequence
(Fig. 2E). This observation indicated that both HLA class I and
II-restricted neoepitopes were elicited by OCDC vaccination.
We demonstrated that adding both ASA and low-dose IL-2 to an
OCDC-Bev-Cy combinatorial regimen increased the proportion of
polyfunctional vaccine-specific CD8+ T cells in OC patients.
The addition of ASA and low-dose IL-2 to an OCDC-Bev-Cy
combinatorial regimen prolongs survival and enhanced tumor
infiltration of cytolytic CD3+ and CD8+ T cells in an OC mouse
model
We used the syngeneic ID8 OC model to investigate if
observations from our phase I OC patients through the addition
of ASA and low-dose IL-2 to OCDC, Bev, and Cy (hereafter referred
to as “baseline treatment”6) could be replicated in mouse avatars.
Tumor-bearing animals were randomized into three treatment
groups closely mimicking the regimens proposed in the phase I
OC clinical trial (Fig. 3A). All animals received the baseline
treatment. Group C animals receiving additional ASA and low-
dose IL-2 demonstrated a significantly lower tumor burden that
decreased over time compared to Groups A (P= 0.008) and B (P=
0.004) (Fig. 3B). Group C animals also demonstrated the longest
median survival (185 days, P= 0.009) (Fig. 3C, blue line)), while
Group B animals which received ASA without low-dose IL-
2 showed no significant improvement in survival over Group A
(median survival of 147 days vs. 134.5 days) (Fig. 3C, gray and red
lines). Moreover, Group C animals displayed a significantly
prolonged OS, whereas animals treated with monotherapies
exhibited poor OS that was similar to the PBS-treated control
group (Supplementary Fig. 3). Similar to OC patients, the addition
of both ASA and low-dose IL-2 significantly increased the overall
efficacy of the baseline treatment in the treated animals.
As T cells help controlling OC, we hypothesized that a larger
number of TILs would be present in Group C than in other groups as
the former showed the lowest tumor burden and longest OS. Seventy
Table 1. Ovarian cancer (OC) patients’ characteristics and treatment details.
















B-01 53 59 ± 9 Ovarian IIIC 2 1 Optimal No 20 Alive
B-02 54 Ovarian IV 5 2 Sub Yes 8 Deceased
B-03 65 Ovarian IV 3 1 Optimal No 11 Deceased
B-04 49 Ovarian IIIC 3 1 Sub Yes 5 Deceased
B-05 44 Ovarian IIIC 2 2 Optimal No 11 Deceased
B-06 61 Fallopian IIC 2 1 Optimal Yes 11 Alive
B-07 74 Ovarian IIIC 4 2 Optimal No 17 Deceased
B-08 57 Ovarian IIIC 3 1 Sub Yes 5 Alive
B-09 69 Ovarian IIIC 4 1 Optimal No 5 Deceased
B-10 67 Ovarian IIIC 3 1 Optimal Yes 5 Alive
C-01 60 56 ± 11 Ovarian IIIC 2 1 Optimal Yes 30 Alive
C-02 57 Ovarian IV 3 1 Optimal Yes 5 Deceased
C-03 54 Ovarian IIIC 2 1 Sub Yes 28 Alive
C-04 72 Ovarian IIIC 3 1 Sub Yes 11 Alive
C-05 73 Peritoneal IIIC 2 1 Optimal No 2 Alive
C-06 37 Ovarian IIIC 5 1 Sub Yes 3 Alive
C-07 46 Ovarian III 2 1 Optimal No 8 Alive
C-08 50 Ovarian III 6 2 Sub Yes 3 Deceased
C-09 52 Ovarian IIIC 5 1 Optimal Yes 8 Alive
C-10 65 Peritoneal IIIC 6 1 Optimal Yes 9 Alive
*Sub indicated a suboptimal secondary debulking.
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Fig. 2 The addition of ASA and low-dose IL-2 to an OCDC-Bev-Cy combinatorial regimen elicits polyfunctional T-cell responses in OC
patients. A Examples in patient C-07 of polyfunctional OCDC vaccine-specific CD4+ and CD8+ T-cell responses elicited. B Cumulative
functional profiling of OCDC vaccine-specific CD4+ and CD8+ T-cell responses where cytokine-producing T cells (as shown in (A)) in response
to ex vivo OCDC stimulation were evaluated for (co)expressions of different functional markers as illustrated by the colored arcs. Pie charts
represented in shades of gray depicting the number of markers coexpressed by OCDC vaccine-specific T cells in Cohort B and C patients (n= 6
patients per cohort). C Cytokine-producing CD4+ and CD8+ T cells following ex vivo OCDC stimulation were evaluated for (co)expression of
the different activation/exhaustion markers as illustrated by the colored arcs. Pie charts in shades of gray depicted the number of markers
coexpressed on the OCDC vaccine-specific T cells in patients. N= 6 patients. D Identification of neoepitope-specific CD4+ and CD8+ T-cell
responses in Cohort B-08 patient. Neoepitopes from the peptide pool were described in Supplementary Table S1. E Bar charts showed the
validation of the IFN-γ ELISpot T-cell response against the (STELMRRVSRFQIAQ [Mut]) neoepitope as well as the lack of response against the
wild-type (STELMRRVRRFQIAQ [WT]) cognate peptide. P values for SPICE pies were determined with Wilcoxon rank-sum test. P < 0.05 was
considered significant, while P > 0.05 was not significant (NS).
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days post-tumor implantation, Groups A, B, C, and PBS-treated
animals were sacrificed and tumors (if any) excised for immuno-
histochemistry (IHC) analysis (Supplementary Fig. 4 showing single
color and merged images). We demonstrated significantly higher
numbers of CD3+ (P= 0.039, P= 0.006, and P= 0.025 as compared
to Groups A, B, and PBS-treatment, respectively) and CD8+ (P=
0.005, P= 0.023, and P= 0.003 as compared to Groups A, B, and
PBS-treatment, respectively) TILs in Group C (Fig. 4A, right panel).
We also detected significantly higher percentages of perforin-
expressing CD3+ (P= 0.011, P= 0.034, and P= 0.023 as compared
to Group A, B, and PBS-treatment, respectively) and CD8+ (P=
<0.0001, P= 0.0002, and P= 0.0002 as compared to Groups A, B,
and PBS-treatment, respectively) TILs in total CD3+ and CD8+ TILs,
respectively, in Group C (Fig. 4A, left panel. IHC images indicating
CD3+CD8+perforin+ T cells with white arrows). By comparing to
Groups A (P= 0.050), B (P= 0.049), and PBS-treatment (P= 0.006),
Group C demonstrated the lowest percentage of tumor-infiltrating
CD3+CD4+Foxp3+ Treg cells in total CD4+ TILs (Fig. 4B, right panel.
IHC images indicating CD3+CD4+Foxp3+ Treg cells with white
arrows). Group C also showed the highest ratio of CD8+ TILs to
tumor-infiltrating Treg cells (all P < 0.0001 when compared to
Groups A, B, and PBS-treatment), suggesting a more favorable TME
for effector T-cell responses than in other groups (Fig. 4B, left
panel). Next, we hypothesized that FasL expressions were
attenuated in Groups B and C animals that received ASA and
anti-VEGF antibody as we had demonstrated in a previous study19.
Indeed, we observed significantly less numbers of FasL+CD31+
tumor endothelial cells in Groups B and C when compared to Group
A (vs. Group B: P= 0.031; vs. Group C: P= 0.008) and PBS-treatment
(vs. Group B: P= 0.006; vs. Group C: P= 0.002) (Fig. 4C, left panel).
We also observed an inverse correlation between reducing
numbers of FasL+CD31+ endothelial cells and increasing numbers
of CD8+ TILs in agreement with our previous study19 (r2= 0.454;
P= 0.033; Fig. 4C, right panel. IHC images indicating FasL+CD31+
endothelial cells with yellow arrows, and CD8+ TILs with white
arrows). Thus, adding both ASA and low-dose IL-2 to the OCDC-Bev-
Cy combinatorial regimen significantly increased total and perforin-
expressing CD3+ and CD8+ TILs infiltrations while reducing tumor-
infiltrating Treg cells. As with our previous study, the inclusion of
ASA and anti-VEGF antibody significantly reduced tumor endothe-
lial FasL expression that in turn was positively correlated with
increased CD8+ TILs infiltration.
Next, we evaluated the plasma chemokine profiles and demon-
strated a significant increase in post-treatment CCL5 (RANTES),
Fig. 3 The addition of ASA and low-dose IL-2 to an OCDC-Bev-Cy combinatorial regimen prolongs survival and reduces tumor burden in
the ID8 ovarian tumor model. A Syngeneic 8–10 weeks old female C57BL/6 mice were implanted i.p. with ID8 tumor cells (5 × 106 cells/
animal) and randomized into Group A, B, or C. All animals received Cy (40mg/kg, indicated as diamonds, given i.p.) before each OCDC, and
anti-VEGF blocking antibody (2mg/kg, clone B20-4.1.1, mouse IgG2a, given intraperitoneally [i.p.]) together with each OCDC. Group B and C
received ASA via drinking water (100mg/kg). Group C also received recombinant mouse low-dose IL-2 (15 µg/kg, given i.p.) on 2 consecutive
days following OCDC vaccination. Five weekly OCDCs were given intradermally in the groin region (1 × 106 DCs/50 µl sterile PBS/animal).
B Quantification of tumor burden with bioluminescence imaging. Results were reported as total flux (photons per second). The tumor burden
of Group C was significantly lower when compared to Group A (P= 0.008) and B (P= 0.004). One-way ANOVA and Tukey’s multiple
comparisons test for significance were performed. C Comparison of the survival curves of animals receiving different regimens (P= 0.009; Log-
rank Mantel–Cox test). Group C showed the longest median OS of 185 days. In all the analyses, P < 0.05 was considered significant. The data
were representative of three separate experiments. Total n= 9 animals per group.
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CCL4 (MIP-1β), CCL2 (MCP-1), and CXCL9 (MIG) (Fig. 4D and
Supplementary Fig. S5A, paired Student’s t tests). In particular,
Group C demonstrated a significant increase in all of these
chemokines when compared to Groups A and B (Fig. 4D). Moreover,
Group C treatment induced the highest total amount of plasma
Th1-polarizing chemokines and CXCL9 when compared to Groups
A, B, and PBS-treatment (Fig. 4E). We demonstrated a significant
positive correlation between an increased level of plasma CXCL9
and the number of tumor-infiltrating CD3+ and CD8+ T cells
(Fig. 4F). No positive correlations were observed for the other
chemokines (Supplementary Fig. S5B). Thus, the addition of both
ASA and low-dose IL-2 to the OCDC-Bev-Cy combinatorial regimen
induced a Th1-polarizing sera chemokine profile, particularly CXCL9
that was conducive for the recruitment of CD3+ and CD8+ TILs for
tumor control.
Adding ASA and low-dose IL-2 to an OCDC-Bev-Cy
combinatorial regimen enhances tumor neoantigen-specific
T-cell responses
We previously demonstrated that OC patients receiving the baseline
treatment elicited tumor neoantigen-specific T cells6, and we could
further validate this finding in a patient in this study (Fig. 2D, E). As
limited patient samples were available, we sought to evaluate
neoantigen-specific T-cell responses in the ID8 model. We
hypothesized that the addition of ASA and low-dose IL-2 to the
baseline treatment could further enhance neoantigen recognition
by T cells. Using ID8 tumor cells, we identified 213 somatic
nonsynonymous mutations and of which 17 neoantigens were
selected following in silico and in vitro validations (Fig. 5A and
Supplementary Table S2). We focused on MHC Class I-restricted
epitopes in the mice as well-established tools for in silico and in vitro
validations were available as compared to those for MHC Class II-
restricted epitopes. After a 7 day in vitro expansion of mouse
splenocytes, we detected CD8+ T-cell IFN-γ responses to 11 of these
neoantigens across all the regimens (Fig. 5B). Group C animals
treated with additional ASA and low-dose IL-2 recognized 10 of
these 11 neoantigens and elicited a significantly higher number of
IFN-γ-secreting T cells against LNPEP, NDUFS6, MYO15, and CDK15
when compared to Groups A and B animals (P < 0.05) (Fig. 5B, third
panel from left, indicated with asterisks). Overall, Group C elicited
the highest number of IFN-γ-secreting neoantigen-specific T cells,
while Group B demonstrated no significant difference with the
baseline treatment group (Fig. 5C). By evaluating the number of
neoantigen-specific CD8+ T cells elicited by each individual
neoantigen and tumor burden measured 70 days post-tumor
implantation (3 weeks post-last treatment) in the animals, we
demonstrated a positive correlation between an increasing number
of IFN-γ-secreting CD8+ T cells recognizing LNPEP, NDUFS6, MYO15,
and CDK15 (individually and as a sum) and decreasing tumor
burden. On the other hand, CD8+ T cells recognizing other tumor
neoantigens did not show such correlation (Fig. 5D and Supple-
mentary Fig. S5). Lastly, we did not observe any significant changes
in the peripheral Treg cell population in all the groups (Supple-
mentary Fig. S6; A showing gating strategy and B % peripheral Treg
cells). Taken together, the addition of both ASA and low-dose IL-2 to
the baseline treatment elicited more IFN-γ-secreting tumor
neoantigen-specific T cells. This combinatorial approach elicited
T cells against specific neoantigens (LNPEP, NDUFS6, MYO15, and
CDK15) that were positively correlated with reduced tumor burden
in the treated animals.
DISCUSSION
A combinatorial therapeutic strategy in OC that targets not only
the tumor but also its TME is strongly warranted. Here, we
presented evidence that the combinatorial use of ASA, low-dose
IL-2, OCDC, Bev, and Cy (Cohort C regimen) increased the
magnitude as well as the polyfunctional profile of OCDC
vaccine-specific CD4+ and CD8+ T cells that were positively
correlated with increased time-to-progression and 3-years OS in
OC patients. Specific polyfunctional CD4+ and CD8+ T cells
characterized by perforin, granzyme B, IFN-γ, and/or TNF-α
expressions were elicited only in Cohort C patients. A higher
3-year OS rate was also observed in Cohort C (80%) than in
Cohorts A and B receiving OCDC-Bev-Cy (40%) and ASA-OCDC-
Bev-Cy regimens (40%), respectively (Cohort A data not shown).
Analysis of the ID8 OC model revealed a similar trend as in the
OC patients whereby animals receiving ASA, low-dose IL-2, OCDC,
anti-VEGF antibody (Bev), and Cy (Group C) demonstrated
prolonged survival and reduced tumor burden. Tumor control
by T cells was evident in these animals as significant infiltrations of
CD3+ and CD8+ TILs including perforin-expression TILs were
observed. Increased CD8+ TILs could be explained in part with
ASA+ anti-VEGF antibody treatment; in agreement with our
previous study19, tumor endothelial FasL expression was reduced
in Groups B and C animals receiving these two agents, and a
positive correlation with increased CD8+ TILs was also observed.
Similar to advanced human OCs, we found a high percentage of
tumor-infiltrating Treg cells (~40% of total CD4+ TILs) in untreated
(PBS) animals. As Treg cells could dampen the functions and
tumor infiltration of effector T cells, we incorporated Cy in the
regimens aiming to deplete Treg cells32,33. We observed moderate
to marked reductions of tumor-infiltrating Treg cells in Groups A,
B, and C that received Cy when compared to the PBS-treated
group. Cy could provide additional benefits as it was shown to
synergize with anti-VEGF antibody through so-called vascular
normalization for Cy to better access tumor sites34,35 to disrupt
tumor vasculature and exert anti-angiogenesis effects36.
Fig. 4 Adding ASA and low-dose IL-2 to OCDC-Bev-Cy combinatorial regimen enhances CD3+ and CD8+ TILs in the ID8 OC model. Eight-
to-ten-week-old female C57BL/6 mice (5 × 106 cells/animal/injected i.p.) were randomized into Group A, B, or C. A Three weeks post-last
treatment, tumors were evaluated with IHC for CD3+ and CD8+ TILs (left panel) and % perforin-expressing CD3+ and CD8+ TILs in total TILs
(middle panel). Representative images showing CD3+CD8+perforin+ T cells (right panel; white arrows). B Percentage of tumor-infiltrating
CD3+CD4+Foxp3+ Treg cells in total CD4+ TILs (left panel), and the ratio of CD8+ TILs to tumor-infiltrating Treg cells (middle panel). Left panel,
images showing CD3+CD4+Foxp3+ Treg cells (white arrows). C Quantification of FasL+CD31+ tumor endothelial cells (left panel). Middle
panel, linear regression analysis indicated an inverse correlation between decreasing numbers of FasL+CD31+ tumor endothelial cells and
increasing numbers of CD8+ TILs. Left panel, images showed FasL+CD31+ endothelial cells (yellow arrows) and CD8+TILs (white arrows). Data
are representative of three separate experiments (n= 3 mice/group). One-way ANOVA and Tukey’s multiple comparisons test for significance
were performed, and *, **, and *** denoted significant P < 0.05, P < 0.01, and P < 0.001, respectively. D Blood samples were collected a day
before any treatment (baseline) and 3 weeks post the last treatment. Plasma was evaluated for Th1-related chemokines (CCL5, CCL4, CCL2,
and CXCL9) in a cytokine bead array. Boxplots compared chemokine concentrations at baseline and 3 weeks post-last treatment (paired
Student’s t test; * and ** denoted significant P < 0.05 and <0.001, respectively). E Post-treatment total Th1-related plasma chemokines and
CXCL9 were presented as mean ± SEM. One-way ANOVA and Tukey’s multiple comparisons test for significance were performed. F Linear
regression analysis indicated an inverse correlation between increasing numbers of CD3+ TILs (r2= 0.690; P= 0.002) (left panel) and CD8+ TILs
(r2= 0.562; P= 0.008) (right panel) with increasing plasma CXCL9. Plasma chemokine data were representative of three separate experiments
(n= 11–12 mice/group).
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Prolonged survival in Group C, as compared to Groups A and B,
could be explained in part by the use of low-dose IL-2. It is
reasonable to postulate that IL-2, a major T-cell growth factor,
assists in the function and proliferation of OCDC vaccine-primed
T cells. We observed improved vaccine-primed T-cell functions as
demonstrated by increased polyfunctionality in Cohort C patients
and increased neoantigen recognition and IFN-γ production in
Group C animals. We also detected the highest numbers of CD3+
and CD8+ TILs, of which up to 40% was associated with a cytolytic
functional profile, in Group C. Coupled with a low number of
tumor-infiltrating Treg cells, Group C displayed a more favorable
OC TME for tumor control than other groups as demonstrated by a
significantly higher ratio of CD8+ TILs to tumor-infiltrating Treg
cells. We also postulated that low-dose IL-2 augmented IFN-γ
production in Group C animals, which the latter in turn induced
CXCL9 which is an important chemoattractant of activated natural
killer and Th1 cells into inflammation sites37 and for anti-
angiogenesis38. Indeed, IFN-γ produced by vaccine-primed
T cells and plasma CXCL9 was significantly increased in Group C.
We also demonstrated that increasing plasma CXCL9 was
positively correlated with increasing CD3+ and CD8+ TILs. Optimal
ex vivo preparation of DC vaccines could also assist in eliciting
Fig. 5 Adding ASA and low-dose IL-2 to OCDC-Bev-Cy combinatorial regimen enhances tumor neoantigen-specific T-cell responses.
A Identification of MHC Class I-restricted neoantigens in ID8 ovarian tumor line. Seventeen of 216 single-nucleotide variants (SNVs) identified
were considered immunogenic and tested in the IFN-γ ELISpot. B Three weeks post-last treatment, splenocytes were cultured with a pool of
17 neoantigen peptides (1 µg/ml per peptide) identified in (A). After 7 days, purified CD8+ T cells were evaluated in ELISpot for their ability to
recognize individual neoantigen in the pool. In each experiment, three animals in the same group were pooled to obtain sufficient CD8+
T cells. Each dot represented the number of IFN-γ secreting spots/1 × 105 CD8+ T cells of a pooled sample recognizing a neoantigen peptide.
The results were subtracted from its respective unstimulated CD8+ T cells alone control. IFN-γ response was considered positive if it was
above the threshold line based on its respective irrelevant melanoma TRP-2 peptide as a negative control (calculated as mean ± 3 × standard
deviation). The results were reported as SFU/1 × 105 CD8+ T cells. One-way ANOVA and Tukey’s multiple comparisons test for significance were
performed, and * denoted P < 0.05 was significant. C Graph showed the mean number of IFN-γ-secreting neoantigen-specific CD8+ T cells
elicited against the 11 neoantigens that showed reactivity in (B). Each dot represented IFN-γ response from a pooled CD8+ T-cell sample
responding to a neoantigen. Results were reported as mean ± SEM. D Right panel showed linear regression analysis indicating a positive
correlation between tumor burden (bioluminescence total flux (photon per second)× 109) and the total number of IFN-γ spots elicited by
neoantigens LNPEP, NDUFS6, MYO15, and CDK15 (r2= 0.721; P= 0.004). Left panel, no positive correlation was observed for the rest of the
neoantigens (r2= 0.023; P= 0.695). The data were representative of three separate experiments with n= 9 animals/group. P < 0.05 was
considered significant, while P > 0.05 was not significant (NS).
J.L. Tanyi et al.
9
Published in partnership with the Sealy Institute for Vaccine Sciences npj Vaccines (2021)    36 
beneficial antitumor as demonstrated by Kalinski et al.39,40. They
demonstrated that type 1-polarized DCs (DC1s) matured ex vivo in
the presence of IFNs and toll-like receptor agonists were more
effective than “standard” DCs that were matured ex vivo in the
presence of PGE2; while both types of DCs were effective in
inducing CD8+ T-cell expansion, DC1s in particular enabled
primed T cells to acquire cytolytic function and peripheral-type
chemokine receptors such as CCR5 and CXCR3 (receptor for
CXCL9)39. Indeed, the OCDC vaccine was prepared by using IFN-γ
and lipopolysaccharides (LPS; TLR 4 agonist) as maturation stimuli
and previously shown to produced a high level of IL-12p70 for
priming T cells5. Activating DCs with other type 1-polarizing
stimuli would be an interesting area to pursue.
Regarding ASA, a recent ASPREE trial demonstrated that healthy
elderly individuals (≥70 years old) who used ASA daily for at least
4 years experienced increased cancer deaths41. More studies are
needed to address the effects of ASA in elderly individuals. Such
information would be useful in designing future OC trials involving
ASA use in elderly OC patients. IL-2 is useful for expanding effector
T cells in cancer therapy, however, it is also found to expand Treg
cells in low-42 and high dose43–45. We did not observe an increased
expansion of peripheral blood Treg cells in patients nor in animals
receiving low-dose IL-2. Further studies are warranted to address
this dual effect of IL-2 in OC cancer therapy.
Similar to our previous study6, we demonstrated that
neoantigen-specific T cells were elicited in an OC patient and in
the ID8 model. Recently, Martin et al. reported that an ID8-G7
tumor model (modified to express ovalbumin) failed to give
rise to any neoantigen that facilitated long-term survival in the
immunized animals46. The authors identified 92 single-nucleotide
variants (SNVs) of which 39 were transcribed missense mutations.
They showed that 7 of the top 17 predicted MHC class I binding
neoantigens induced robust CD4+ and/or CD8+ T-cell response
but none prolonged the survival of animals in prophylactic and
therapeutic settings. We used the wild-type ID8 cell line (no
ovalbumin expression) and identified 216 SNVs, of which 17 were
immunogenic following in silico and in vitro validations. We
demonstrated that 11 of these neoantigens induced IFN-γ
responses, and 4 of them were associated with reduced tumor
burden in Group C. Differences in our results could be explained
by the fact that we and Martin et al. discovered different sets of
neoantigens through the use of different algorithms for neoanti-
gen predictions; we developed an in-house algorithm that
adapted Burrows–Wheeler Aligner (BWA) and Genome Analysis
Toolkit (GATK) to analyze murine genome sequences, whereas
Martin el al. utilized the Structure Motif Analysis tool (SMAtool) for
their neoepitope predictions. We also used different ID8 cell lines
(wild-type ID8 vs. ID8-G7) for whole-exome and RNA sequencing.
Although we detected more SNVs (216 vs. 92), we and Martin et al.
found only 17 immunogenic neoantigens following in vitro MHC
binding in agreement that OC is an intermediate/low mutational
burden tumor. None of the neoantigens (LNPEP, NDUFS6, MYO15,
and CDK15) we found that was associated with reduced tumor
burden was identified by Martin et al. Interestingly, we and
Martin et al. identified a neoantigen from Tle1 gene that failed to
elicit T-cell responses in the animals. Our results demonstrated
that targeting neoantigens is beneficial in OC. This also high-
lighted a strong need to optimize and standardize neoantigen
prediction algorithms to improve their accuracy for long-term
translational use.
As the single therapy approach has so far shown minimal efficacy
in OC, a combinatorial approach is highly warranted. We demon-
strated that the combinatorial use of ASA, low-dose IL-2, OCDC, Bev,
and Cy was efficacious in OC. We provided evidence that adding ASA
and IL-2 to the OCDC-Bev-Cy combinatorial regimen could modulate
the OC TME to augment OCDC vaccine-primed T-cell responses. We
detected increased cytolytic TILs and reduced tumor-infiltrating Treg
cells, favoring a Th1-polarizing TME. Reduced tumor endothelial FasL
expression and increased plasma CXCL9 were positively correlated
with increased TILs, further augmenting Th1-polarizing responses.
Through this co-clinical small-scale study, we also demonstrated that
the syngeneic ID8 tumor model could serve as a useful tool for
predicting different therapeutic strategies in OC for future clinical
trial designs.
METHODS
Clinical trial design and patient cohorts
Patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer
were enrolled in phase I, a single-center study comprised of various
sequential cohorts (NCT01132014). The primary objective was to establish
the safety and biological activity of OCDC, a vaccine prepared from
autologous DCs pulsed with oxidized autologous whole-tumor lysate, in
combination with Bev, Cy, ASA, and/or low-dose IL-2 (Fig. 1A). OCDC
preparation was previously described5,6. Thirty patients were enrolled (ten
patients per cohort). Cohort A received intravenous Cy (200mg/m2)
followed by OCDC (5–10 × 106 DCs/dose given intranodally every 3 weeks,
five doses in total) plus intravenous Bev (anti-VEGF blocking antibody,
15mg/kg, given on the same day as OCDC) on the next day every 3 weeks.
Cohort B received the above regimen plus oral ASA (325mg of enteric-
coated aspirin from the day of first OCDC to day 84 or as tolerated).
Subcutaneous low-dose IL-2 (2MIU/dose given for 5 consecutive days
following each OCDC) was given to Cohort C in addition to the regimen
described for Cohort B. Twelve to 15 weeks post-OCDC vaccination,
patients with no evidence of disease or stable disease were offered a
maintenance regimen. Patients with progressive diseases went off the
study. Additional inclusion criteria required that patients were ≥18 years
old, had sufficient tumor previously harvested at secondary cytoreductive
surgery for lysate preparation, had completed physician’s choice
chemotherapy after secondary debulking and had a baseline Eastern
Cooperative Oncology Group (ECOG) performance status 0–1. After
enrolment, patients underwent 10–15 liters apheresis to harvest elutriated
monocytes for OCDC production. All the patients were followed up for 3
years. The study was approved by the US FDA (BB-IND-14269) and by the
University of Pennsylvania’s Institutional Review Board. All patients gave
written informed consent before initiation of any study procedures.
Patient OCDC vaccine manufacturing, vaccination, and
monitoring
OCDC vaccines were generated at the Clinical Cell and Vaccine Production
Facility (CVPF) at the University of Pennsylvania as previously described5,6.
Following 10–15 liters of apheresis, the patient’s PBMCs were elutriated
(fraction 5) and the monocytes cultured in CellGenix DC media (CellGenix,
Germany), 2% human pooled AB serum (Valley Biomedical Inc., Winchester,
USA), L-glutamine (2mM), penicillin (100 U/ml), streptomycin (100 μg/ml;
Cellgro), clinical-grade human GM-CSF (500 IU/ml; Sargramostim, Bayer
Healthcare Pharmaceuticals), and animal-free research-grade IL-4 (250 IU/ml;
R&D Systems). Day 4, output cells were evaluated for DC markers CD11c
(clone B-ly6), CD14 (clone M5E2), and HLA-DR (clone L243) (all from BD
Biosciences) and were found to be >70% pure. Following overnight pulsing
with hypochlorous acid (HOCl)-oxidized autologous whole-tumor lysate, the
DCs were activated with LPS (60 EU/ml; Escherichia coli O:113; a gift from A.
Suffredini at the National Institutes of Health (NIH)] and recombinant human
IFN-γ (2000 IU/ml; InterMune, California, USA). OCDC vaccines met the release
criteria in all the patients. Vaccine aliquots (~5–10 × 106 DCs per dose) were
cryopreserved at −140 °C, thawed, and washed before each administration.
Patients received five doses of OCDC vaccines intranodally every 3 weeks
under ultrasound guidance and continued on a monthly maintenance
regimen until disease progression or exhaustion of vaccine supply. Safety was
determined using the National Cancer Institute Common Terminology Criteria
for Adverse Events version 4.0. Patients underwent a CT scan at enrolment
and on day 114 (EOS). Clinical response was based on the Response
Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-related response
criteria. Patients continued with either maintenance vaccination plus Bev and
Cy ± ASA± low-dose IL-2, or went off the study. Blood samples were collected
from all patients prior to treatment for baseline immune assessment (pre-
treatment; pre-VAX), during the study, and at EOS (post-treatment).
All patients’ samples were transferred and analyzed at the Center of
Experimental Therapeutics (CTE) at the Lausanne Branch of the Ludwig
Institute for Cancer Research.
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IFN-γ ELISpot of human OCDC vaccine-specific and neoantigen
T cells
We successfully collected PBMCs from 12 of 20 patients enrolled in Cohorts
B and C (6 from each cohort) at various time points specified in Fig. 1A for
analysis. To evaluate IFN-γ-secreting OCDC vaccine-specific T cells before
(pre-vax; day −1), during (day 20 and 62) and after (EOS) treatment in
these patients, cryopreserved PBMCs were thawed, rested overnight in
Roswell Park Memorial Institute (RPMI) 1640 media containing 10% fetal
bovine serum (FBS), penicillin (100 U/ml) and streptomycin (100 μg/ml) at
37 °C, 5% CO2 (all from Invitrogen, CA, USA). The next day, the OCDC
vaccine was thawed, washed, and immediately added to PBMCs at 1
ODCD:10 PBMCs ratio in pre-coated 96-well Enzyme-Linked ImmunoSpot
(ELISpot) plates (Mabtech AB, France) and evaluated. For IFN-γ-secreting
neoantigen-specific T-cell analysis in patient B-08, cryopreserved PBMCs
from EOS were thawed, washed, and stimulated with neoepitope
(STELMRRVSRFQIAQ) or wild-type (STELMRRVRRFQIAQ) cognate peptide
(1 µg/ml per peptide) in RPMI media containing penicillin (100 U/ml),
streptomycin (100 μg/ml), 2-mercaptoethanol (50 µM), and 8% AB pooled
human serum (Biowest, France). Recombinant human IL-2 (100 IU/ml,
Proleukin®, Bayer HealthCare Pharmaceuticals, CA, USA) was added after
48 h. Day 12, IFN-γ ELISpot assays were performed. PBMCs stimulated with
Staphylococcal Enterotoxin (SEB) served as positive controls, while PBMCs
stimulated with media were used as background controls. In total, 2 × 105
PBMC were plated in duplicates or triplicate for each condition. After
16–18 h of stimulation, the plates were washed according to the
manufacturer’s instruction and counted with AID-Spot Robot ELISpot
reader (AutoImmun Diagnostika GMBH, Germany). Results were expressed
as spots-forming units (SFU) per 1 × 106 PBMCs.
Flow cytometry analysis of human OCDC vaccine-specific and
neoantigen T cells
To determine the phenotype and cytokine profiles of OCDC vaccine-specific
CD4+ and CD8+ T cells by flow cytometry, patients’ cryopreserved PBMCs
were thawed and rested overnight in RPMI media containing 10% FBS,
penicillin (100 U/ml) and streptomycin (100 μg/ml) at 37 °C, 5% CO2. The next
day, autologous OCDC vaccine was thawed, washed with RPMI, 10% FBS, and
immediately added to the PBMCs at 1 OCDC:10 PBMCs ratio in the presence
of brefeldin A (1 µg; BD Biosciences, San Jose, USA) and for 16–18 h
incubation at 37 °C, 5% CO2. Then, the cells were washed with PBS and
stained for 20min on ice with anti-CD3 (clone SK7; Biolegend), anti-CD8 (clone
RPA-T8; Biolegend), anti-CD4 (clone RPA-T4; BD Biosciences), anti-CD137 (4-
1BB, clone 4B4-1; Biolegend), and a viability dye (Zombie UV, Biolegend). After
fixation and permeabilization step (BD Cytofix/Cytoperm Kit) for 20min at
4 °C, cells were intracellularly stained with anti-Granzyme B (clone GB11;
Invitrogen, CA, USA), anti-Perforin (clone B-D48; Biolegend), anti-IL-2 (clone
MQ1-17H12; BD Biosciences), anti-TNF-α (clone MAb11; BD Biosciences), and
anti-IFN-γ (clone B27; BD Biosciences) for 20min on ice. In another staining
panel, cells were stained intracellularly with anti-IL-17 (clone BL168; Biolegend)
and anti-Ki-67 (clone B-ly6; BD Biosciences). To determine exhaustion markers,
the cells were stained for 20min on ice with anti-CD3 (Biolegend), anti-CD8
(Biolegend), anti-CD4 (BD Biosciences), anti-PD1 (clone EH12.2H7; Biolegend),
anti-TIM3 (clone 344823; R&D Systems, MN, USA), anti-LAG-3 (clone 17B4;
Enzo Life Sciences (ELS) AG, Switzerland), anti-TIGIT (clone 741182, R&D
Systems), anti-2B4/CD244 (clone C1.7; Biolegend) and a viability dye (Zombie
UV, Biolegend). After fixation and permeabilization treatment as described
above, cells were intracellularly stained with anti-CTLA-4 (clone BNI3; BD
Biosciences) for 20min on ice.
To determine intracellular TNF-α and IFN-γ profile of neoantigen-specific
CD4+ and CD8+ T cells in patient B-08, cryopreserved PBMCs were thawed,
washed, and stimulated the cells for 16–18 h with neoantigen peptide pool
(final concentration of 1 µg/ml per peptide; Supplementary Table S1) using
same the culture condition as described for this patient’s ELISpot analysis.
PBMCs stimulated with media alone were used as a background control,
while PBMCs stimulated with anti-CD3 antibody (final concentration of
1 µg/ml, 4 °C overnight; clone OKT3, Mabtech) were used as a positive
control. The cells were stained as described above.
To determine Treg cell markers in patients’ PBMCs at EOS, cells were
stained for 20min on ice with anti-CD8 (Biolegend), anti-CD3 (Biolegend),
anti-CD4 (BD Biosciences), anti-CD25 (clone 2A3; BD Biosciences), anti-TIGIT
(R&D Systems), anti-CD45A (clone HI100; BD Biosciences), anti-CD127
(clone R34.34; Beckman Coulter, France), anti-CD39 (clone A1; Biolegend),
and viability dye Zombie UV (Biolegend). After fixation and permeabiliza-
tion treatment (eBiosciences Foxp3 kit) for 30min at 4 °C, cells were
intracellularly stained with anti-Foxp3 (clone 236 A/E7; eBiosciences) and
anti-Helios (clone 22F6, Biolegend). After the last staining step, all the
samples were washed twice with PBS before acquiring on a 5-laser BD
Fortessa instrument equipped with the FACS Diva software. The analysis
was performed with FlowJo v10.5 (FLOWJO.LLC) and SPICE 5.1 software.
Human neoepitope predictions
Whole-exome sequencing analyses for mutation calling and high-
resolution HLA typing were performed as previously described47.
MixMHCpred.v2.0.2 and MixMHC2pred.v1 was used to predict the binding
of candidate peptides incorporating somatic nonsynonymous mutations
and their wild-type counterparts (8–12 mer peptides to HLA class I alleles
and 12–19 mer peptides to HLA Class II alleles)48–50. Predicted mutated
peptides were prioritized based on the following parameters (by
decreasing order of importance): predicted binding rank, the median
expression of the gene in healthy ovarian tissues in GTEx51, the
representation of the peptide in ipMSDB52. Peptides with binding rank
>5%, gene expression in GTEx < 1TPM, and peptides with low representa-
tion in ipMSDB (<4 class I and class II peptides) were removed from the list.
The peptides were grouped by source gene. The best peptides of each
gene and for each HLA allele were selected for further analysis.
Synthesis of human and mouse neoantigen peptides
Human candidate neoepitopes and their wild-type counterpart peptides were
synthesized at >90% high-performance liquid chromatography (HPLC) purity.
For mouse ID8, 10-mer candidate neoepitope peptides were synthesized at
≥79% HPLC purity. All peptides were synthesized at the Protein and Peptide
Chemistry Facility (PPCF), University of Lausanne, Switzerland.
Mouse cell line
The ID8 cell line, derived from spontaneous in vitro malignant
transformation of C57BL/6 mouse ovarian surface epithelial cells (gift from
Prof. Iain McNeish, University of Glasgow, UK), closely represents human
high-grade serous OC in terms of disseminated peritoneal tumors and
ascites fluid formation53. It was maintained in Dulbecco’s modified Eagle’s
medium (DMEM) containing 4% FBS, penicillin (100 U/ml), streptomycin
(100 µg/ml) (all from Invitrogen), and 1% insulin–transferrin–selenium (ITS-
G; Gibco, Thermo Fisher Scientific, MA, USA) at 37 °C, 5% CO2. It was tested
regularly for mycoplasma and found to be negative.
Mouse OCDC vaccine preparation
Mouse OCDC vaccine preparation was previously described5. Briefly, bone
marrow cells from mouse femurs and tibias were cultured at 1–2 × 106
cells/ml in complete Iscove’s Modified Dulbecco’s Medium (IMDM)
containing 10% FBS, 50 µM 2-mercaptoethanol, 100 U/ml penicillin,
100 µg/ml streptomycin (all from Invitrogen), and 1000 IU/ml recombinant
mouse granulocyte–macrophage colony-stimulating factor (GM-CSF;
PeproTech, UK). Day 3, floating cells representing granulocytes were
removed, and fresh complete IMDM and 1000 IU/ml GM-CSF were added.
Day 5, recombinant mouse IL-4 (100 IU/ml; PeproTech, UK) was added. Day
6, HOCl-oxidized ID8 tumor cell lysate were cocultured with DCs at 1:1 ratio
for 20 h. DCs were stimulated with lipopolysaccharide (LPS) [120 EU/ml,
Escherichia Coli O:113; InvivoGen Europe, France] and IFN-γ (4000 IU/ml;
PeproTech, UK) for 16 h and used. HOCl oxidation of ID8 tumor lysate was
previously described (ref. 5; main paper). Briefly, 60 µM HOCl solution was
prepared by diluting the stock NaOCl reagent (Sigma-Aldrich Chemie
GmbH) with PBS (Invitrogen) and adding immediately to ID8 cells to give
1 × 106 cells/ml. ID8 cells were incubated for 1 h at 37 °C, 5% CO2 to induce
oxidation-dependent cell death, and then subjected to six freeze–thaw
cycles to complete cell fragmentation before coculturing with DCs.
In vivo treatments in mice
Syngeneic 8–10-week-old female C57BL/6 mice (Envigo, France) were
implanted with 5 × 106 ID8 tumor cells intraperitoneally (i.p.) in 200 µl of
sterile saline and randomized into Group A, B, or C to receive specific
treatments (Fig. 3A). In all groups, tumor-bearing animals received Cy
(40mg/kg, prepared in sterile PBS and given i.p.; Sigma-Aldrich Chemie
GmbH, Switzerland) a day before each OCDC and anti-VEGF antibody
(2mg/kg, clone B20-4.1.1 mouse IgG2a, prepared in sterile PBS and given
i.p.; Absolute Antibody, UK) together with each OCDC. In Groups B and C,
animals were given ASA via drinking water (100mg/kg, assuming daily
consumption of ~3ml at 0.7 mg/ml prepared in sterile deionized water54;
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Sigma-Aldrich Chemie GmbH). In Group C, animals received recombinant
mouse IL-2 (15 µg/kg, prepared in sterile PBS given i.p.; PeproTech, UK) on
two consecutive days following OCDC vaccination. OCDC was given
intradermally in the groin region (1 × 106 DCs/50 µl sterile PBS/mouse). As
controls, tumor-bearing animals were treated with PBS only following the
Group C schedule. As treatment controls, tumor-bearing animals were
treated with Cy, anti-VEGF antibody, ASA, low-dose IL-2 only, or Cy+anti-
VEGF antibody following Group C schedule. Animals were weighed at least
twice weekly and euthanized when their body weight exceeded >20% as a
surrogate endpoint for survival or when they became distressed and
moribund in compliance with the institutional animal care guidelines. For
neoantigen T-cell responses, animals were sacrificed 3 weeks after the last
treatment (70 days post-tumor implantation). Animal experimentation
procedures were performed according to the animal protocols approved
by the Veterinary Service of Canton Vaud, Switzerland.
Qualification of ID8 tumor burden with bioluminescence
imaging
ID8 tumor cells (5 × 106/mouse) expressing luciferase were injected i.p.
into 8–10-week-old C57/BL6 female mice as described earlier. Day 19
post-tumor implantation and before the first treatment, tumor burden was
measured by bioluminescence quantification of luciferase activity
(reported as photons/sec). Bioluminescence imaging (Xenogen IVIS lumina
II, PerkinElmer, Switzerland) was performed once every 2 weeks thereafter
before the onset of ascites formation in PBS-treated control mice.
ID8 tumor somatic nonsynonymous mutations identification
and validation
Genomic DNA and RNA from ID8 tumor cells and DNA from C57BL/7
mouse ear tissue were isolated using DNeasy or RNeasy kits (Qiagen AG,
Switzerland) following the manufacturer’s instructions. Whole-exome
sequencing was performed (Fasteris SA, Switzerland). Somatic nonsynon-
ymous mutations in the ID8 tumor cell were identified using a pipeline by
aligning the whole-exome sequences to the reference C57BL/6J mouse
genome using Burrows–Wheeler Aligner (BWA), and performing variant-
calling with Genome Analysis Toolkit (GATK) as previously6 but modified
for murine genome sequences. The mutations were evaluated with in silico
predictions with NetMHC (version 4.0) and NetMHCpan (version 3.0), and
ranked according to their binding affinity to the mouse MHC class I H-2Db
and H2Kb alleles. Gene expressions of the identified somatic mutations
were determined with RNA sequencing. Additional filtering of the
neoepitope candidates was performed according to their gene expression
with RNA sequences alignment (STAR) and gene annotation (GENCODE).
Finally, the top 2% of the neoepitopes that showed a higher binding
affinity to MHC Class I (H2-Db and/or H2Kb) than their wild-type
counterpart and were expressed in at least two out of the three triplicates
were selected for further validation. Following that, in vitro ELISA assay was
performed as previously described to determine the candidate neoepitope
binding to MHC Class I H2-Db and H2Kb alleles55. Immunogenic
neoepitopes were used in the mouse interferon (IFN)-γ ELISpot.
Multiplex immunohistochemistry staining of ID8 OC tumors
Three weeks after the last treatment (70 days post-tumor implantation),
mice were sacrificed and freshly dissected ID8 OC tumors were fixed in 4%
paraformaldehyde solution for 24 h at room temperature. To prepare
paraffin-embedded tissue blocks, the tumors were dehydrated through
70%, 80%, and 95% alcohol (45min each), followed by three changes of
100% alcohol (1 h each), clearing through two changes of xylene (1 h each)
and finally immersed in three changes of paraffin (1 h each). Sections of
paraffin-embedded tissue blocks (5-µm thick) were prepared on a
microtome and transferred onto glass slides for multiplex immunohisto-
chemistry. The slides were dried overnight and stored at 4 °C until ready for
use. Multiplex IHC assays were performed on a VENTANA DISCOVERY Ultra
automated staining instrument (Roche Diagnostics, Indianapolis, USA),
using VENTANA reagents except as noted, according to the manufacturer’s
instructions and as previously described56. The following primary
antibodies against mouse markers were used: (a) anti-CD3 (rat monoclonal,
clone SP7, Abcam plc, UK); (b) anti-CD8 (rat monoclonal, clone 4SM15,
Thermo Fisher Scientific, Switzerland); (c) anti-CD4 (rat monoclonal, clone
4SM95, Thermo Fisher Scientific); (d) anti-CD31 (rat monoclonal,
clone SZ31, Dianova GmbH, Germany); (e) anti-perforin (rat monoclonal,
clone CB5.4, Abcam plc); (f) anti-FOXP3 (rat monoclonal, clone FJK-16s,
Thermo Fisher Scientific); (g) anti-WT1 (rabbit monoclonal, clone CAN-R9
(IHC)-56-2, Abcam plc); and (h) anti-FasL (rabbit polyclonal, Bioss
Antibodies, Massachusetts USA). The following secondary antibodies
were used: (a) ImmPRESS® horseradish peroxidase (HRP) goat anti-rat IgG
(Vector Laboratories, CA, USA), (b) ImmPRESS® HRP horse anti-rabbit IgG
(Vector laboratories). The slides were mounted with Fluoromount-G™
mounting medium containing DAPI (Thermo Fisher Scientific) and
analyzed within 48 h.
Multispectral imaging and data analysis
Multiplex immunofluorescence (IF) images were acquired on the Vectra®
Polaris automated quantitative pathology imaging system (Akoya Bios-
ciences, Marlborough, MA, USA), allowing the unmixing of spectrally
overlapping fluorophores and tissue autofluorescence of whole slide scans.
For the optimal IF signal unmixing (individual spectral peaks) and the
subsequent multiplex analysis, a spectral library containing the individual
emitting spectral peaks of all the five to six fluorophores were created and
validated using the inForm Analysis software (Akoya Biosciences). The
phenotyping analysis was performed using inForm 2.4.8 image analysis
software (Akoya Biosciences) enabling a per-cell analysis of weak and/or
spectrally overlapping IF markers of multiplex-stained tissue sections.
The images were first segmented into specific tissue categories of the
tumor, stroma, and no tissue, based on the WT1 (OC tumor antigen
expressed on ID8 tumor cells) and DAPI staining using the inForm Tissue
Finder™ algorithms. Then, individual cells were segmented using the
counterstained-based adaptive cell-segmentation algorithm. Quantifica-
tion of the immune cells was finally performed using the inForm active
learning phenotyping algorithm by assigning the different cell phenotypes
across several images representative of the whole scan. InForm software
was trained to recognize cell phenotypes according to these three staining
panels: (1) panel 1—CD8-, CD3-, WT1-, Perforin-positive cells; (2) panel 2—
CD4-, CD3-, WT1-, Foxp3-positive cells; and (3) panel 3—CD8-, WT1-, FasL-,
CD31-positive cells. This algorithm was then applied on the whole scan by
batch to quantify all the different cell types and a home-made R-script is
then used to retrieve all combined phenotype cells and scoring in an
output excel file.
Mouse peripheral blood Treg cell staining
About 50 µl of blood per draw was collected into Lithium heparin-coated
Eppendorf tubes (Fisher Scientific AG, Switzerland) on ice and centrifuged
at 1500 × g for 15min at 4 °C. Red cells were removed with
ammonium–chloride–potassium (ACK) lysis buffer (Sigma-Aldrich Chemie
GmbH, Switzerland), washed twice with PBS and blocked with staining buffer
(PBS containing anti-mouse CD16/CD32 at 1 µg/ml) for 10min on ice. Then,
cells were stained with anti-CD3 (clone 17A2, eBioscience), anti-CD4 (clone
RM4-5, eBioscience) and anti-CD25 (clone PC61, eBioscience) for 30min on
ice. Following that, cells were subjected to fixation and permeabilization
treatment (eBioscience) for 30min at 4 °C and stained overnight with anti-
Foxp3 (clone FJK-16s, eBioscience). The next day, cells were washed twice
with staining buffer, collected on the same day, and interrogated using BD
Canto flow cytometer (Becton Dickinson). Data were analyzed with Pro
CellQuest software. T cells that were positive for CD3, CD4, CD25, and Foxp3
were expressed as a percentage of all the CD4+ T cells.
Mouse plasma chemokine bead array analysis
To measure the plasma chemokines, about 50 µl of blood per draw was
collected a day prior to any treatment (baseline) and 3 weeks after the last
treatment (day 70 post-tumor implantation). The blood samples were
processed as described above. The top phase that consisted of the plasma
was carefully removed to avoid any leukocytes and red cells and stored at
−80 °C until ready to use. The plasma chemokines were evaluated with the
LEGENDplex™ Mouse Proinflammatory Chemokine Panel following the
manufacturer’s protocol (Biolegend, San Diego, CA, USA).
IFN-γ production by mouse neoantigen-specific T cells
Three weeks after the last treatment, mouse splenocytes were harvested
and cultured with a pool of 17 neoantigen peptides (1 µg/ml per peptide)
identified in the ID8 cell line (Supplementary Table S2). Splenocytes were
cultured in complete RPMI media containing 10% FBS, 2-mercaptoethanol
(50 µM), penicillin (100 U/ml), and streptomycin (100 µg/ml) and recombi-
nant mouse IL-2 (300 IU/ml; PeproTech). Fresh IL-2 and complete RMPI
media were replenished every 2–3 days. Day 8, CD8+ T cells in the cultures
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were isolated by negative selection (Miltenyi Biotec Swiss AG, Switzerland)
and assessed in IFN-γ ELISpot assay for their ability to recognize specific
neoantigen peptides. In each experiment, three mice in the same group
were pooled to obtain sufficient CD8+ T cells. Irradiated splenocytes
from normal mice served as antigen-presenting cells (APCs) and pre-
pulsed with individual neoantigen peptide (1 µg/ml) before coculturing
with CD8+ T cells at a ratio of 10 T cells:1 APC for 16 h at 37 °C. CD8+ T cells
exposed to phorbol 12‐myristate 13‐acetate (PMA) and ionomycin (both
from Sigma-Aldrich Chemie GmbH) served as positive controls. CD8+
T cells alone served as background and T cells cocultured with irradiated
APCs pulsed with melanoma tyrosinase-related protein (TRP)-2 served
as irrelevant peptide controls. ELISpot was performed following the
manufacturer’s protocol (Mabtech AB). The number of IFN-γ-producing
cells was counted with AID-Spot Robot ELISpot reader (AutoImmun
Diagnostika GMBH) and expressed as SFU per 1 × 105 mouse CD8+ T cells.
After subtracting the count from its respective background, a positive
neoantigen peptide response was determined as having more spots
than its respective irrelevant TRP-2 peptide control+ 3× standard
deviation (SD).
Statistical analysis
Median survival times were computed using Kaplan–Meier methods and
the log-rank test. The analysis of variance (ANOVA) was used to compare
more than two groups. When the ANOVA was significant, Tukey’s multiple
comparison test was used to conduct pairwise comparisons unless
otherwise stated. A two-tailed Student’s t test (paired and unpaired) was
used to compare means of continuous measurements between two
groups. Differences were considered statistically significant when P < 0.05.
GraphPad Prism 8 (San Diego, CA, USA) was used. Flow cytometry data
were analyzed with FlowJo v10.5 (FlowJo, LLC) and SPICE 5.1 software57.
P values for SPICE pies were determined with Wilcoxon rank-sum test.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
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